FDA Approval Status for Pediatrics
Tigecycline, a glycylcycline antibiotic used for complicated skin/skin structure infections and intra-abdominal infections in adults, lacks full FDA approval for children under 18. The agency approved it only for patients 8 years and older in specific cases, like complicated intra-abdominal infections caused by certain bacteria, based on limited pediatric data.[1] It's not approved for those under 8 due to insufficient safety and efficacy studies.
Clinical Trial Data in Kids
Trials involved about 270 children aged 8-17, showing tigecycline worked similarly to comparators like vancomycin for infections, with cure rates around 80-90%.[2] No new safety signals emerged beyond adult profiles, but sample sizes were small, limiting long-term insights. Younger kids (under 8) have no trial data, as bone growth risks from tetracycline-class drugs prompted exclusion.
Common Side Effects and Pediatric Concerns
Kids experience similar issues as adults: nausea (25-30%), vomiting (15-20%), diarrhea, and elevated liver enzymes.[3] Rare but serious risks include superinfections (e.g., C. difficile), pancreatitis, and hypersensitivity. Tooth discoloration and enamel hypoplasia occur with tetracyclines in under-8s, though tigecycline shows less in studies—still a regulatory holdback. No unique pediatric mortality spikes, but IV administration raises infusion-related reactions.
When Doctors Use It Off-Label
Pediatric infectious disease experts prescribe it off-label for multidrug-resistant infections (e.g., Acinetobacter, carbapenem-resistant Enterobacteriaceae) when options fail, per IDSA guidelines favoring it in limited scenarios.[4] Dosing: 1.2 mg/kg every 12 hours (max 50 mg). Hospitals monitor closely for GI tolerance and resistance emergence.
Alternatives for Children
| Drug Class | Examples | Approved Ages | Key Use Cases |
|------------|----------|---------------|--------------|
| Carbapenems | Meropenem, Imipenem | All ages | Broad-spectrum resistant infections |
| Beta-lactam combos | Piperacillin-tazobactam | Neonates+ | Intra-abdominal, skin infections |
| Cephalosporins | Cefepime | All ages | Gram-negative coverage |
| Newer agents | Ceftazidime-avibactam | 3 months+ | CRE infections |
Consult pediatric ID specialists; tigecycline ranks low on first-line lists due to bacteriostatic action and poor lung penetration.
Ongoing Research and Gaps
Phase 3 trials (e.g., NCT04594158) test tigecycline in younger kids for hospital-acquired pneumonia, with results due 2025.[5] European EMA mirrors FDA limits. Parents report variable tolerance online, but real-world data lags.
[1]: FDA Label for Tygacil
[2]: Pediatric Pharmacokinetics Study, Clin Infect Dis 2019
[3]: Safety Review, Pediatr Infect Dis J 2020
[4]: IDSA Guidance on MDR Gram-Negatives
[5]: ClinicalTrials.gov NCT04594158